The Lipid Droplet as a Potential Therapeutic Target in NAFLD

被引:43
|
作者
Goh, Vera J. [1 ]
Silver, David L. [1 ]
机构
[1] Duke NUS Grad Med Sch, Signature Res Program Cardiovasc & Metab Disorder, Singapore 169857, Singapore
基金
英国医学研究理事会;
关键词
nonalcoholic fatty liver disease; lipid droplets; triglyceride; FATTY LIVER-DISEASE; SEIP CONGENITAL LIPODYSTROPHY; TRIGLYCERIDE TRANSFER PROTEIN; PPAR-GAMMA; ENDOPLASMIC-RETICULUM; INSULIN-RESISTANCE; HEPATIC STEATOSIS; APOLIPOPROTEIN-B; PHOSPHATIDYLCHOLINE SYNTHESIS; TRIACYLGLYCEROL SYNTHESIS;
D O I
10.1055/s-0033-1358521
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is a growing problem worldwide. Nonalcoholic fatty liver disease is characterized by an abnormal accumulation of triglyceride-rich lipid droplets (LDs) in the liver, which can lead to liver inflammation and metabolic disturbances. Lipid droplets are dynamic organelles that have recently gained considerable scientific interest. Their formation and growth are regulated processes requiring the participation of many endoplasmic reticulum- (ER-) and LD-associated proteins, which may serve as potential therapeutic targets for NAFLD. Protein families such as fat-inducing transmembrane proteins 1 and 2 (FITM1/FIT1 and FITM2/FIT2), the CIDE family of proteins, and the perilipin family, play important roles in LD biology. In this review, the authors discuss current views on LD formation and growth, and how various proteins may affect LD metabolism and lipoprotein assembly in the pathogenesis of NAFLD.
引用
收藏
页码:312 / 320
页数:9
相关论文
共 50 条
  • [21] Gut microbiome and NAFLD: impact and therapeutic potential
    Li, Liwei
    Cai, Fuqing
    Guo, Chen
    Liu, Zheng
    Qin, Jiamin
    Huang, Jiean
    FRONTIERS IN MICROBIOLOGY, 2024, 15
  • [22] Moderate Treadmill Exercise Alleviates NAFLD by Regulating the Biogenesis and Autophagy of Lipid Droplet
    Yang, Yangjun
    Li, Xi
    Liu, Zonghan
    Ruan, Xinyu
    Wang, Huihui
    Zhang, Qiang
    Cao, Lu
    Song, Luchen
    Chen, Yinghong
    Sun, Yi
    NUTRIENTS, 2022, 14 (22)
  • [23] Galectin-3 in NAFLD: Therapeutic Target or Noncausal Biomarker?
    Soccio, Raymond E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3773 - E3774
  • [24] Role and effective therapeutic target of gut microbiota in NAFLD/NASH
    Liu, Qun
    Liu, Shousheng
    Chen, Lizhen
    Zhao, Zhenzhen
    Du, Shuixian
    Dong, Quanjiang
    Xin, Yongning
    Xuan, Shiying
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (03) : 1935 - 1944
  • [25] EZH2 as a Potential Target for NAFLD Therapy
    Lim, Hyun Jung
    Kim, Mirang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 15
  • [26] Lipid Droplet—a New Target in Ischemic Heart Disease
    Xiaoying Guo
    Qi Shi
    Wanqin Zhang
    Zhongwen Qi
    Hao Lv
    Fujing Man
    Yingyu Xie
    Yaping Zhu
    Junping Zhang
    Journal of Cardiovascular Translational Research, 2022, 15 : 730 - 739
  • [27] Lipid A as a Drug Target and Therapeutic Molecule
    Joe, Sang Hoon
    BIOMOLECULES & THERAPEUTICS, 2015, 23 (06) : 510 - 516
  • [28] Kidney lipid metabolism as a therapeutic target
    Nuesken, Kai-Dietrich
    NEPHROLOGIE, 2022, 17 (04): : 261 - 262
  • [29] Potential Therapeutic Targets and Promising Agents for Combating NAFLD
    Umemura, Atsushi
    Kataoka, Seita
    Okuda, Keiichiro
    Seko, Yuya
    Yamaguchi, Kanji
    Moriguchi, Michihisa
    Okanoue, Takeshi
    Itoh, Yoshito
    BIOMEDICINES, 2022, 10 (04)
  • [30] Lipid-signaling as a Potential New Therapeutic Target in Chronic Obstructive Pulmonary Disease
    Vesely, P. W.
    Thanh, H. Phan Thi
    Kanti, M.
    Subramaniyan, B.
    Moore, A.
    Georgescu, C.
    Wren, J. D.
    Freeman, W. M.
    Syarif, A. Hutami
    Schauer, S.
    Schweiger, M.
    Kwapiszewska, G.
    Hoefler, G.
    Walters, M. S.
    Marsh, L. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209